![Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2022/04/08/2022.04.06.487285/F1.large.jpg)
Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv
![Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/3/1/Slide03.jpg)
Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice
![Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/2094227228/2077090889/gr1.gif)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet
![The shifting roles and toxicities of cellular therapies in B‐cell malignancies - Makos - Transplant Infectious Disease - Wiley Online Library The shifting roles and toxicities of cellular therapies in B‐cell malignancies - Makos - Transplant Infectious Disease - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/db8495ba-f4ef-4d9d-bb2d-d33a508debaa/tid.v25.4.cover.jpg?trick=1694107121211)
The shifting roles and toxicities of cellular therapies in B‐cell malignancies - Makos - Transplant Infectious Disease - Wiley Online Library
![Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/3/1/Slide10.jpg)
Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice
![Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale - Dürig - 2023 - Cancer Medicine - Wiley Online Library Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale - Dürig - 2023 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ec0a755d-86c6-4e22-8b7d-a7e0c5e0a3f0/cam45160-toc-0001-m.jpg?trick=1688992257010)
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale - Dürig - 2023 - Cancer Medicine - Wiley Online Library
LYMPHOCARE- The Cancer Rehab/ best Lymphedema/ Cancer/ Cancer exercise/ Specialist/ Doctor/Therapist/ Near me/ In Gurugram - Physiotherapist in Gurugram
![Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/c880e7d6-3884-4edd-a1bc-b882d7c24b3c/gr2_lrg.jpg)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology
![Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | Annals of Hematology Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | Annals of Hematology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04021-6/MediaObjects/277_2020_4021_Fig4_HTML.png)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | Annals of Hematology
![Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/3/1/Slide04.jpg)
Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice
![Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989–2016 | Leukemia Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989–2016 | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-020-01048-6/MediaObjects/41375_2020_1048_Fig1_HTML.png)
Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989–2016 | Leukemia
LYMPHOCARE- The Cancer Rehab/ best Lymphedema/ Cancer/ Cancer exercise/ Specialist/ Doctor/Therapist/ Near me/ In Gurugram - Physiotherapist in Gurugram
![Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/3/1/Slide02.jpg)
Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
![PDF] Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). | Semantic Scholar PDF] Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/acfb0c49e62bc861029ae15f97530c20aacd4c8b/26-Table2-1.png)
PDF] Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). | Semantic Scholar
![Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | Annals of Hematology Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | Annals of Hematology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04021-6/MediaObjects/277_2020_4021_Fig2_HTML.png)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | Annals of Hematology
![Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis - Biology of Blood and Marrow Transplantation Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis - Biology of Blood and Marrow Transplantation](https://www.astctjournal.org/cms/attachment/4d982194-d95a-4575-af5a-20f54abbbfa0/ybbmt54956-fig-0001_lrg.jpg)
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis - Biology of Blood and Marrow Transplantation
![PDF) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study PDF) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study](https://www.researchgate.net/profile/Christopher-Flowers/publication/279629395/figure/tbl2/AS:601627316744198@1520450538202/Characteristics-of-Patients-in-the-NLCS-by-Group_Q320.jpg)
PDF) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
![Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study - ScienceDirect Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419363720-gr1.jpg)
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study - ScienceDirect
![Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/3/1/Slide12.jpg)
Analysis of the National LymphoCare Study Evaluating Early Disease Progression in Patients with FL within 2 Years of R-CHOP | Research To Practice
![PDF) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study PDF) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study](https://i1.rgstatic.net/publication/279629395_Early_Relapse_of_Follicular_Lymphoma_After_Rituximab_Plus_Cyclophosphamide_Doxorubicin_Vincristine_and_Prednisone_Defines_Patients_at_High_Risk_for_Death_An_Analysis_From_the_National_LymphoCare_Study/links/57dbd5bc08ae5292a37978be/largepreview.png)
PDF) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
![Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study | Journal of Clinical Oncology Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2015/jco.2015.61.33.issue-23/jco.2014.59.7534/20161107/images/medium/zlj02315-5358-t02.jpeg)